… in the treatment of non-small cell lung cancer (NSCLC) have … advancing early detection and
multimodal care. The use of small … However, the overall cure and survival rates for NSCLC …

… The WHO divides lung cancer into 2 major classes based on its biology, therapy, and
prognosis: NSCLC and small cell lung cancer (SCLC; see the NCCN Guidelines for Small …

… Drugs approved by the FDA for the treatment of non-small-cell lung cancer. ALK, anaplastic
lymphoma kinase; EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors; …

… cancer cases in the United States. After the initial diagnosis, accurate staging of non-small
cell lung cancer using … is crucial for determining appropriate therapy. When feasible, surgical …

… Non-small cell lung cancer (NSCLC) accounts for the majority of all … There are two main
subtypes of lung cancer, small-cell lung carcinoma and non-small-cell lung carcinoma (NSCLC), …

… lung cancer there have been advances in many aspects of the classification, diagnosis, and
treatment of non-small-cell lung cancer … and more effective treatment of the disease, and the …

… therapy, irrespective of histological subtype, without any option for further lines of treatment.
… , docetaxel, and paclitaxel, treatment of non-small-cell lung cancer changed, and overall …

… , lung cancer is the most common cause of cancer-related deaths. Molecular targeted therapies
and immunotherapies for non-small-cell lung cancer … to current treatments and eventually …

… of care for fit stage I non-small cell lung cancer (NSCLC) patients. Adjuvant treatment should
… In advanced stage IIIB/IV or inoperable NSCLC pts, a multidisciplinary treatment should be …

… Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in the … ,
including squamous cell carcinoma, adenocarcinoma and large cell carcinoma, its represents …